Pavel Dřevı́nek

Elexacaftor–Tezacaftor–Ivacaftor for Cystic Fibrosis with a Single Phe508del Allele

Peter G. Middleton, Marcus Mall, Pavel Dřevı́nek et al. · New England Journal of Medicine · 2019 · 2.1K citations · Full text

Life Sciences, Pharmacology, Pharmacotherapy +16

Factors associated with FEV₁decline in cystic fibrosis: analysis of the ECFS Patient Registry

Eitan Kerem, Laura Viviani, Anna Zolin et al. · European Respiratory Journal · 2013 · 296 citations · Full text

Health Professions, Infectious Diseases, Clinical Epidemiology +16

Long-term safety and efficacy of ivacaftor in patients with cystic fibrosis who have the Gly551Asp-CFTR mutation: a phase 3, open-label extension study (PERSIST)

Edward F. McKone, Drucy Borowitz, Pavel Dřevı́nek et al. · The Lancet Respiratory Medicine · 2014 · 211 citations

Medicine, Pharmacology, Pharmacotherapy +16

Environmental<i>Burkholderia cepacia</i>Complex Isolates from Human Infections

Adam Baldwin, Eshwar Mahenthiralingam, Pavel Dřevı́nek et al. · Emerging infectious diseases · 2007 · 124 citations · Full text

Life Sciences, Infectious Diseases, Microbiology +13

Report of the European Respiratory Society/European Cystic Fibrosis Society task force on the care of adults with cystic fibrosis

J.S. Elborn, Scott C. Bell, Susan Madge et al. · European Respiratory Journal · 2015 · 117 citations · Full text

Medicine, Medical Education, Health Care Leadership +16